Upgrade to SI Premium - Free Trial

Aerie Pharma (AERI) Roclatan 0.02%/0.005% Phase 3 Trial Achieves Primary Efficacy Endpoint

May 24, 2017 4:12 PM
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News

Next Articles